Introduction
When Congress passed the 2025 Continuing Resolution and rewrote the federal definition of hemp, it came with a built-in requirement for the FDA: within 90 days of enactment, the agency was mandated to publish three specific lists — naturally occurring cannabinoids, THC-class cannabinoids, and all known cannabinoids with THC-like effects.
The deadline was February 10, 2026. It came and went without a published list.
For the hemp industry, this silence isn’t just bureaucratic delay — it has real implications for compliance, enforcement, and ingredient sourcing. Here’s what we know and what it means for B2B buyers.
What the FDA Was Required to Publish
The 2025 Continuing Resolution was unusually specific in its requirements for the FDA. The agency was directed to publish:
- A list of naturally occurring cannabinoids — those compounds that the cannabis plant produces without human synthesis or chemical conversion.
- A list of THC-class cannabinoids — compounds that are structurally or pharmacologically similar to delta-9 THC.
- A list of cannabinoids with THC-like effects — including compounds that may not be structurally identical to THC but produce similar physiological effects.
These lists were intended to be foundational to enforcement. Without them, the line between a “naturally occurring” hemp cannabinoid and a “synthesized” or “converted” compound remains unclear — which creates gray areas that both brands and regulators are navigating in the dark.
Why the FDA Hasn’t Published the Lists
There are several plausible explanations for the delay, none of which are officially confirmed:
Scientific complexity. Defining the universe of naturally occurring cannabinoids is a genuinely difficult scientific task. The cannabis plant has been documented to produce over 100 distinct cannabinoids, and the science on which compounds are “naturally occurring” versus “hemisynthetic” is not fully settled.
Enforcement resource constraints. Both FDA and DEA have publicly acknowledged that they may lack the resources to broadly enforce the new hemp rules. Publishing a list that triggers enforcement actions the agency can’t follow through on would create its own problems.
Interagency coordination. The cannabinoid lists affect DEA scheduling, FDA food and supplement regulation, and FTC marketing standards simultaneously. Cross-agency coordination takes time.
Political dynamics. With bipartisan delay bills in Congress and industry lobbying intensive, the FDA may be taking a wait-and-see posture on enforcement-related guidance.
What the Missing Lists Mean for Hemp Brands
For brands selling hemp-derived products, the absence of FDA cannabinoid lists creates a specific kind of uncertainty:
Novel or semi-synthetic cannabinoids are in limbo. Compounds like delta-8 THC, THCO, and hexahydrocannabinol (HHC) exist in a gray area — some argue they are naturally occurring in trace amounts, others argue they require synthetic production processes. Until FDA publishes its lists, there’s no authoritative federal position.
Non-intoxicating cannabinoids remain safer ground. CBD isolate, CBG, CBN, and broad-spectrum hemp extracts that test below the total THC threshold are on firmer footing, regardless of the missing lists. These compounds have long histories of regulatory treatment as hemp-derived ingredients.
The container limit still applies. Even without the published cannabinoid lists, the 0.4mg total THC per container requirement is in effect as of November 12, 2026. Brands should not interpret the FDA’s silence as relief from the container limit.
How Ingredient Suppliers Can Help Bridge the Gap
In the absence of clear FDA guidance, sophisticated hemp ingredient suppliers play an increasingly important role. Here’s what B2B buyers should be asking their suppliers:
- Can you provide documentation distinguishing naturally occurring cannabinoids from converted or synthetic derivatives in your products?
- Do your COAs test for total THC, including THCA converted via the 0.877 decarboxylation factor?
- How are you tracking the cannabinoid list development and updating your ingredient specifications accordingly?
Suppliers who can answer these questions — with documentation, not just verbal assurances — are the partners worth prioritizing as the November deadline approaches.
What to Watch at FDA
Several developments would signal that FDA is moving toward publishing the required lists:
- Federal Register notices calling for public comment on cannabinoid classification
- Guidance documents from FDA’s Center for Food Safety and Applied Nutrition (CFSAN) on hemp-derived ingredients
- Enforcement actions targeting specific cannabinoids, which often precede formal rulemaking
- Congressional hearings pressing FDA leadership on the missed deadline
Until those signals appear, hemp brands should operate on the assumption that the published lists are still months away.
🌿 LGH Perspective
The FDA’s silence is concerning, but it doesn’t change our approach. At Low Gravity Hemp, we source and test for naturally derived cannabinoids with full traceability documentation. We don’t work with converted or semi-synthetic cannabinoid inputs, which means our ingredient portfolio is positioned to remain compliant regardless of how the FDA ultimately defines the cannabinoid categories. Our B2B customers can buy with confidence.
Final Thoughts
The FDA’s missed deadline on cannabinoid lists is a real compliance complication — but it’s not a reason to pause compliance planning. If anything, it’s a reason to work with ingredient suppliers who can provide maximum transparency about sourcing and compound origins. The brands that invest in that kind of supplier relationship now will be far better positioned when the FDA does publish its guidance.
Want to review your ingredient sourcing against the upcoming federal hemp standards? Reach out to our team at Low Gravity Hemp.
